Biocept (BIOC) Misses Q3 EPS by $0.03

Go back to Biocept (BIOC) Misses Q3 EPS by $0.03

Biocept Reports Third Quarter 2021 Financial Results

November 15, 2021 4:05 PM EST

Revenues for the third quarter of $17.5 million, up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end Robust CNSide sequential-quarter volume growth; continued customer base expansion Data generated by leading cancer center demonstrates superior performance of CNSide versus standard of care

Conference call begins at 4:30 p.m. Eastern time today

SAN DIEGO--(BUSINESS... More